Viatris Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-11$16.13 RISE2026-03-30$12.96 PEAK2026-05-07$17.39 85d | -19.7% 47d | Missed | Missed | — | — | +34.2% 38d | Missed |
DROP2024-11-27$13.22 RISE2025-04-10$7.26 PEAK2025-07-02$9.34 217d | -45.1% 134d | Missed | Missed | — | — | +28.7% 83d | Missed |
DROP2024-02-23$13.53 RISE2024-06-18$10.05 PEAK2024-07-30$12.13 158d | -25.7% 116d | Missed | Missed | — | — | +20.7% 42d | Missed |
DROP2023-08-11$11.35 RISE2023-10-27$8.77 PEAK2024-01-10$12.10 152d | -22.7% 77d | Missed | Missed | — | — | +38.0% 75d | Missed |
DROP2023-02-01$12.26 RISE2023-05-04$9.02 PEAK2023-07-24$10.62 173d | -26.4% 92d | Missed | Missed | — | — | +17.7% 81d | Missed |
DROP2022-05-31$12.27 RISE2022-09-27$8.48 PEAK2022-11-14$11.56 167d | -30.9% 119d | 2022-08-10 $10.77 | 2022-11-14 $11.56 | 65Deep Value | 71Deep Value | +36.3% 48d | +7.3% Held 96d |
DROP2022-05-31$12.27 RISE2022-07-22$9.55 PEAK2022-08-12$11.13 73d | -22.2% 52d | 2022-08-10 $10.77 | 2022-08-12 $11.13 | 65Deep Value | 63Deep Value | +16.5% 21d | +3.3% Held 2d |
DROP2022-02-09$15.40 RISE2022-05-06$9.95 PEAK2022-05-31$12.27 111d | -35.4% 86d | Missed | Missed | — | — | +23.3% 25d | Missed |
DROP2022-02-09$15.40 RISE2022-03-14$9.81 PEAK2022-05-31$12.27 111d | -36.3% 33d | Missed | Missed | — | — | +25.1% 78d | Missed |
DROP2021-09-02$15.13 RISE2021-12-01$12.09 PEAK2022-02-09$15.40 160d | -20.1% 90d | Missed | Missed | — | — | +27.4% 70d | Missed |
DROP2020-12-31$18.74 RISE2021-04-13$12.97 PEAK2021-05-17$16.15 137d | -30.8% 103d | Missed | Missed | — | — | +24.5% 34d | Missed |
DROP2020-12-31$18.74 RISE2021-03-04$13.59 PEAK2021-05-17$16.15 137d | -27.5% 63d | Missed | Missed | — | — | +18.8% 74d | Missed |
DROP2020-07-29$17.00 RISE2020-10-28$14.30 PEAK2020-12-31$18.74 155d | -15.9% 91d | Missed | Missed | — | — | +31.0% 64d | Missed |
DROP2020-06-08$18.78 RISE2020-09-24$14.21 PEAK2020-11-19$18.11 164d | -24.3% 108d | Missed | Missed | — | — | +27.4% 56d | Missed |
DROP2020-02-06$22.85 RISE2020-03-12$13.26 PEAK2020-06-08$18.78 123d | -42.0% 35d | Missed | Missed | — | — | +41.6% 88d | Missed |
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026
Viatris (VTRS) is back in focus after the FDA accepted its New Drug Application for MR-107A-02, a fast acting, non opioid meloxicam formulation for moderate to severe acute pain. See our latest analysis for Viatris. Viatris has already been seeing stronger interest, with a 30 day share price return of 14.12% and a 1 year total shareholder return of 108.76%. This suggests momentum is building as investors weigh its pipeline progress against past earnings pressure. If this kind of pipeline...
Viatris (VTRS) is back in focus after the FDA accepted its New Drug Application for MR-107A-02, a fast acting, non opioid meloxicam formulation for moderate to severe acute pain. See our latest analysis for Viatris. Viatris has already been seeing stronger interest, with a 30 day share price return of 14.12% and a 1 year total shareholder return of 108.76%. This suggests momentum is building as investors weigh its pipeline progress against past earnings pressure. If this kind of pipeline...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Recently published Acute Myocardial Infarction Market Insights report includes a comprehensive understanding of current treatment practices, acute myocardial infarction emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network.
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network.
Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed this performance to strong commercial execution, particularly in Greater China, which saw accelerated growth driven by increased demand for cardiovascular products and successful e-commerce investments. CEO Scott Smith highlighted the company's execution and portfolio diversification, noting, “you’re seeing strong execution and our commercial
Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed this performance to strong commercial execution, particularly in Greater China, which saw accelerated growth driven by increased demand for cardiovascular products and successful e-commerce investments. CEO Scott Smith highlighted the company's execution and portfolio diversification, noting, “you’re seeing strong execution and our commercial
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. Acute pain affects more than 80 million individuals in the United States each year, where opioids remain a commonly used treatment option.1,2
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a
Viatris Inc. recently reported first-quarter 2026 results, with sales rising to US$3,509.7 million from US$3,243.2 million and net income improving to US$176.4 million from a net loss of US$3,042 million a year earlier, while reaffirming full-year 2026 revenue guidance of US$14.45 billion to US$14.95 billion and maintaining its quarterly dividend of US$0.12 per share. Alongside these results, Viatris announced the departure of Chief Financial Officer Theodora “Doretta” Mistras and the...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| VTRS | +8.11% | +3.57% | +30.60% | +84.98% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +5.14% | +9.28% | +34.05% | +72.29% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 52.23M | $705.68M | 0.02% | Trimmed-5.6% | 2026-03-31 |
| FidelityFMR | fundamental | 16.59M | $224.11M | 0.01% | Added+9.8% | 2026-03-31 |
| DEShaw | quant | 3.88M | $52.45M | 0.03% | Trimmed-35.7% | 2026-03-31 |
| Citadel | multi-strat | 1.78M | $24.01M | 0.03% | New | 2026-03-31 |
| Bridgewater | macro | 725.9K | $9.81M | 0.04% | Trimmed-49.1% | 2026-03-31 |
| TwoSigma | quant | 200.6K | $2.71M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 65.86M | $889.83K | 0.10% | Trimmed-16.7% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | M Option exercise(deriv) | 3,644 | — | +$0 |
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | M Option exercise(deriv) | 39,344 | — | +$0 |
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | F Tax withholding | 1,617 | $13.86 | −$22.4K |
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | M Option exercise | 3,644 | — | +$0 |
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | F Tax withholding | 17,450 | $13.86 | −$241.9K |
| 2026-04-16 | Le Goff Corinne | Chief Commercial Officer | M Option exercise | 39,344 | — | +$0 |
| 2026-03-24 | Campbell Paul | See Remarks | S Open-market sale | 21,350 | $13.28 | −$283.5K |
| 2026-03-10 | FINNEY ELISHA W | Director | A Grant / award(deriv) | 15,890 | — | +$0 |
| 2026-03-10 | FINNEY ELISHA W | Director | M Option exercise(deriv) | 1,174 | — | +$0 |
| 2026-03-10 | FINNEY ELISHA W | Director | M Option exercise(deriv) | 23,660 | — | +$0 |
| 2026-03-10 | FINNEY ELISHA W | Director | M Option exercise | 1,175 | — | +$0 |
| 2026-03-10 | FINNEY ELISHA W | Director | M Option exercise | 23,660 | — | +$0 |
| 2026-03-10 | CORNWELL W DON | Director | A Grant / award(deriv) | 15,890 | — | +$0 |
| 2026-03-10 | CORNWELL W DON | Director | M Option exercise(deriv) | 1,174 | — | +$0 |
| 2026-03-10 | CORNWELL W DON | Director | M Option exercise(deriv) | 23,660 | — | +$0 |
| 2026-03-10 | CORNWELL W DON | Director | M Option exercise | 1,175 | — | +$0 |
| 2026-03-10 | CORNWELL W DON | Director | M Option exercise | 23,660 | — | +$0 |
| 2026-03-10 | DAMELIO FRANK A | Director | A Grant / award(deriv) | 15,890 | — | +$0 |
| 2026-03-10 | DAMELIO FRANK A | Director | M Option exercise(deriv) | 918 | — | +$0 |
| 2026-03-10 | DAMELIO FRANK A | Director | M Option exercise(deriv) | 25,112 | — | +$0 |
| 2026-03-10 | DAMELIO FRANK A | Director | M Option exercise | 919 | — | +$0 |
| 2026-03-10 | DAMELIO FRANK A | Director | M Option exercise | 25,112 | — | +$0 |
| 2026-03-10 | Vivaldi Coelho Rogerio | Director | A Grant / award(deriv) | 15,890 | — | +$0 |
| 2026-03-10 | Vivaldi Coelho Rogerio | Director | M Option exercise(deriv) | 1,174 | — | +$0 |
| 2026-03-10 | Vivaldi Coelho Rogerio | Director | M Option exercise(deriv) | 23,660 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 0.61 | — | — |
| 2026-05-07 | 0.50 | 0.59 | +17.54% |
| 2026-02-26 | 0.53 | 0.57 | +7.39% |
| 2025-11-06 | -0.03 | -0.11 | -231.03% |
| 2025-08-07 | 0.56 | 0.62 | +11.55% |
| 2025-05-08 | 0.49 | 0.50 | +1.64% |
| 2025-02-27 | 0.57 | 0.54 | -5.60% |
| 2024-11-07 | 0.68 | 0.75 | +10.73% |
| 2024-08-08 | 0.68 | 0.69 | +2.29% |
| 2024-05-09 | 0.67 | 0.67 | -0.41% |
| 2024-02-28 | 0.65 | 0.62 | -4.29% |
| 2023-11-07 | 0.74 | 0.79 | +6.75% |
| 2023-08-07 | 0.71 | 0.75 | +5.44% |
| 2023-05-08 | 0.70 | 0.77 | +10.56% |
| 2023-02-27 | 0.72 | 0.67 | -6.10% |
| 2022-11-07 | 0.84 | 0.87 | +4.26% |